To examine the relationships between bone loss and sex steroids, 84 peri-and postmenopausal women were studied at 4-mo intervals for 3 yr. At each visit, measurements were made of bone mass at the midshaft and distal radius, of steroids, of gonadotropins, and of bone gla protein (BGP). Bone loss was approximately 1% per yr among late perimenopausal and postmenopausal groups, whereas the early perimenopausal group lost no bone. Mean serum estrogen and BGP concentrations predicted rates of bone loss. BGP was negatively correlated with the rate of bone loss (r = -0.45) and with mean estrogen concentrations (r = -0.40). Multivariate regressions showed estrogen concentrations to be strong independent predictors of the slope of bone mass over time. When BGP concentrations were added to the models, the significance of estrogen was reduced, suggesting that a portion of the estrogen effect was mediated through effects on rates of bone remodelling. 
Introduction
It is generally recognized that estrogen deficiency plays a role in the genesis ofpostmenopausal bone loss and the subsequent development of osteoporosis and its attendant fractures. There is controversy, however, regarding the importance ofthe natural menopause and the contribution of residual endogenous estrogen concentrations to rates of bone loss (1) .
Oophorectomy is known to induce a phase of relatively rapid bone loss (2, 3) that is ameliorated with exogenous estrogen therapy (4, 5) . Estrogen therapy has also been shown to reduce the rate of bone loss after natural menopause (6) , as well as to reduce the incidence of vertebral deformities (5, 7). Some case-control studies have suggested that serum estrogens may be lower in patients with crush fractures (8) , whereas others have found no such effect (9-1 1). Despite these results, disagreement still exists regarding the importance of natural menopause and its effects on the rate ofbone loss from various sites. While it has been suggested that trabecular bone may be especially sensitive to the declining estrogen concentrations An Receivedfor publication 10 June 1986 and in revisedform 20 April 1987. that accompany menopause (12) , it has also been argued that the decline in bone mass over time is little altered by menopause, with vertebral bone loss beginning at about age 40 yr and continuing at an approximately constant rate thereafter (13, 14) , although these same authors did find an accelerated appendicular rate of loss in the 51-65-yr age group. This phenomenon of bone loss around the time of menopause appears to affect the entire skeleton, and exogenous estrogen prophylaxis appears to be effective at all sites ( 15).
Published longitudinal studies of changes in bone mass associated with changes in endogenous estrogens are few. The importance of change in estrogen concentrations through menopause is unclear, although there is some suggestion that those who lose bone more rapidly have lower concentrations of estrone (El)' and estradiol (E2) (16) . This study examined changes in bone mass, but made only a single measurement of hormones.
Thus, whether endogenous estrogens determine rates of bone loss through the period surrounding the cessation of menses, and whether the relatively low concentrations of estrogens, which prevail after menopause, continue to be important, remain unanswered questions. Furthermore, a proposed mechanism of the estrogen effect on bone, e.g., increased remodelling when estrogen concentrations decline (17) (18) (19) (20) , has also not been studied longitudinally.
Finally, the importance of other potential influences, such as smoking, obesity, and dietary factors have rarely been studied in conjunction with a longitudinal examination of bone mass and hormones through the menopause. The study de- scribed below examined bone, hormone, and other factors in a group ofwomen prospectively around the time of menopause. Menopausal status was determined by interview and by measurements of gonadotropins. At each visit each volunteer answered questions regarding recent menstrual history. After 1 yr of follow-up, subjects were defined as postmenopausal if there was complete absence of menstrual cycles since the beginning of the study (n = 45). The early postmenopausal (n = 14 of 45) were at entry to the study < 1 yr since the cessation of menses, and the late postmenopausal (n = 31 of 45) were between 1 and 5 yr postmenopausal. The remaining 39 subjects cycled irregularly during this 1st yr and were considered perimenopausal. This group was divided into the late perimenopausal (n = 20), who had concentrations of FSH > 40 mIU/ml on at least two occasions during the 1st yr, and the early perimenopausal (n = 19), who were cycling irregularly but did not show consistently elevated concentrations of FSH. Thus, the menopausal status of subjects in this study was defined based on menstrual history and gonadotropin concentrations during year one of this 3-yr study. 21 subjects from the perimenopausal group became postmenopausal during the last 2 yr of the study.
Single-photon absorptiometry was performed on the midshaft radius at a point one-third ofthe distance from the radial styloid to the olecranon and on the distal radius at 10% of this same distance. The absorptiometry was done using an iodine source with one-eighth-in. beam collimation (21) . The midshaft site is -98% cortical bone, whereas the distal site is -70% cortical and 30% trabecular bone (22) . In vivo precision, assuming linear changes in bone mass, based on 893 radius measurements over 3 yr in 84 women, was 3.1% for the distal and 2.4% for the midshaft measurements.
El, E2, T, and A were measured by radioimmunoassay (23, 24) .
Briefly, 20-ml blood samples were drawn, centrifuged, and analyses done on plasma. The analyses involved solvent extraction and celite chromatography for steroid purification, followed by immunoassay using specific antibodies and dextran-coated charcoal to separate free and bound steroid. Gonadotropins (FSH and LH) were measured using standard kits obtained from Serono (Serono Laboratories Co., Braintree, MA). Metabolic clearance (MCR) and production (PB) rates and conversions [p]J1,P"d or [p] nd8it" were measured as previously described (25, 26 were determined. The mean ofthese two values was used to determine the PB of each steroid. For women who were still having menstrual cycles, the infusions were done in the early-to mid-follicular phase.
Analysis of the plasma samples involved solvent extraction and multiple chromatographic and derivatization steps to achieve radiochemical purity (25) . The radioactivity in each steroid was measured in a liquid scintillation spectrometer and corrected for losses through the procedure as described (26) . The MCRs and PB were calculated as follows (27) : MCR = r/x where r designates rate of infusion (disintegrations per minute per day) and x, mean concentration of infused steroids (disintegrations per minute per liter); PB = MCR X i where i measures concentration of steroid as determined by radioimmunoassays.
Urines were analyzed as described (28) . Briefly, unconjugated steroids were extracted using cyclohexane-ethylacetate (1:2 vol/vol) and the urine was incubated with 3-glucuronidase. The hydrolyzed steroids were extracted with cyclohexane-ethylacetate (1:2 vol/vol) and purified by alkaline partition and multiple chromatographic and derivatization steps. The radioactivity as E1, E2, and estriol was measured using a liquid scintillation spectrometer. [P~gno,.n (the percent of androgen infused that is converted to estrogen in the body) is calcu-
Bone gla protein (BGP) was measured using a method previously described (29) .
Dietary calcium, protein, phosphorus, and caffeine (from chocolate, coffee, tea, and cola soft drinks) were estimated from 3-d diet diaries, coded by registered dietitians and analyzed using a modification ofthe U. S. Department ofAgriculture Handbook 456. Interviews were used to assess smoking, medical and surgical history, alcohol intake, and drug use. Body-mass index (BMI) was calculated as weight (kilogram) divided by height squared (meters squared).
Statistical methods. Rates ofbone loss for each individual, and the inter-and intrasubject variances were calculated according to the method of Hui (30) . Group means were compared using t tests for independent samples with separate variances. Multiple group comparisons were done by analysis of variance with Tukey's test for pairwise contrasts. Pearson correlations and general linear models (weighted by the inverse of the sum of the inter-and intraperson variances) were performed using a statistical analysis package (Statistical Analysis System User's Guide, 1985 Version 5; SAS Inst. Inc., Cary, NC).
Results
Table I displays the mean ages, BMIs, and months since last menses for each of the four groups. The early perimenopausal women were on average 2.6 yr younger than late perimenopausal women (P < 0.05). The late perimenopausal and early postmenopausal groups did not differ significantly in age (0.3 yr). Table II presents the rates of change in bone mass and the mean concentrations of the sex steroids and BGP over 3 yr. The early perimenopausal group was not losing bone at either the midshaft (+0.0005 g/cm per yr) or distal (+0.0067 g/cm per yr) radius, whereas each of the other three groups had rates of bone loss significantly different from zero, and not significantly different from one another; i.e., the late perimenopausal and both postmenopausal groups had not significantly different rates of bone loss. Likewise, the early perimenopausal group had a mean concentration ofBGP at 2 ng/ml lower than the late perimenopausal group (Table II) that in turn differed by only 0.3 ng/ml from the early postmenopausal group and by 0.8 ng/ml from the late postmenopausal group. Similarly, with respect to the estrogens, the early perimenopausal differed significantly from the late perimenopausal by 42 pg/ml (El) and 59 pg/ml (E2), whereas the late perimenopausal group had El concentrations only 6 pg/ml higher and E2 concentrations 16 pg/ml higher than the early postmenopausal group (both NS). There were no consistent patterns across groups with respect to the mean androgen concentrations, although the early perimenopausal group had slightly higher A concentrations. Table III summarizes the PB, MCR, and aromatization rate for the four groups. Again, only the early perimenopausal group was significantly different from any other, having greater PB ofEl and E2 than the late perimenopausal and both postmenopausal groups. The late perimenopausal group did not differ in estrogen production from either of the postmenopausal groups.
MCR and aromatization rate were similar in all four groups (Table III) .
Summarizing Tables I, II , and III, the early perimenopausal women were significantly different from the late perimenopausal and both groups of postmenopausal women with respect to rates of change in bone mass, PB and mean concentrations of the estrogens, and age. Of perhaps greater importance, the late perimenopausal women were not significantly different from the early postmenopausal group on any measured variable, and differed from the late postmenopausal only once (mean E2 concentration). Thus, the late perimenopausal and both postmenopausal groups are combined for some analyses. The purpose of this approach is to examine bone loss in a group with more homogeneous concentrations of El and E2, thereby reducing the possibility that outliers (i.e., those with very high estrogens and low bone loss) might have a disproportionate influence on the results of regression analyses. As shown in Table IV , the early perimenopausal group showed no loss ofbone at either site, whereas the late peri-plus postmenopausal groups (n = 65) lost midshaft bone at 0.93% per yr and distal radius bone at 1. 19% per yr. Similarly, the early perimenopausal group had significantly higher concentrations of El (89.3 vs. 39.4 pg/ml, P < 0.001), and E2 (108.6 vs. 31.5 pg/ml, P < 0.001), and A (0.67 vs. 0.48 ng/ml, P < 0.05).
For the entire study group the rate of change at the midshaft (-0.56 g/cm per yr, -0.66% per yr) was correlated with the rate ofchange at the distal site (-0.64 g/cm per yr, -0.7 1% For the entire study population the correlations between rates of bone loss and mean steroid concentrations, PB measurements, and mean BGP concentrations are shown in Table  V . These correlations are based on the means ofmeasurements (an average of 6.5 measurements per subject) of BGP and an average of 9.0 measurements of the steroids per subject to minimize the effect of within-subject random variation and to reflect average hormone concentration during the period of bone loss. The estrogens, E1 and E2, were correlated at r = +0.90 (P < 0.001). Both the mean concentrations and the PB of the estrogens were correlated with rates of change in bone, more positive slopes (i.e., less bone loss) being seen in Plasma BGP concentrations were also strongly correlated with El (r = -0.42, P = 0.0001) and E2 (r = -0.39, P 0.0002) concentrations. The correlations between other potential influences and rates of bone loss were also examined by univariate analysis. These included pack-years of smoking (years smoking X average packs per day), BMI, alcohol intake, dietary calcium, protein, and caffeine intakes; none was significant in the complete group (n = 84), nor when the group was divided into peri-and postmenopausal. When these variables were included in multivariate models that included estrogen concentrations, none were significantly associated with changes in bone mass.
General linear models (multiple linear regressions) were constructed to predict the slopes ofbone mass over time. Independent variables were selected for inclusion in the models if they were univariately associated with bone loss, if they were associated with bone loss in analysis of variance models, or if they were considered potentially important confounders. These were estrogen and androgen concentrations, dietary calcium and caffeine, pack-years smoking, and height. Age was tested as an independent variable in all models, but was never significant (probably due to the narrow range of ages) and is not included here. BGP was not included in the original models constructed since it was considered to be a reflection of the effects of other independent variables, such as estrogens Original model also included height, caffeine, smoking, and calcium (NS). (Tables I, II, and III) to be similar to the postmenopausal groups, and significantly different in all irhportant respects from the early perimenopausal group, the late perimenopausal and both postmenopausal groups were combined, yielding 65 women whose hormonal characteristics were similar. The mean concentration of El for this group was 39 pg/ml (36 pg/ml for the postmenopausal groups) and of E2, 32 pg/ml (25 pg/ml for the postmenopausal. only). The association of estrogen with bone loss in this relatively estrogen-deficient group was somewhat weaker. Table VIII shows the results of these general linear models. At the midshaft radius, E2 (significant in simple linear regressions that excluded BGP, P = 0.04) was reduced to nonsignificance (P = 0.44) when BGP was included in the model.
At the distal site E2 was not significant, but T concentrations were positively associated with the change in distal bone mass. At both sites, greater concentrations of BGP were strongly associated with greater bone loss. Equally important, these results clearly demonstrate that estrogen concentrations among those relatively estrogen-deficient subjects are associated with the rate of bone loss. When the early perimenopausal group was excluded, mean estrogen concentration remained a univariate predictor of rates of change in bone mass at the midshaft radius. When only postmenopausal visits were considered, a significant association between distal bone loss and estrogen remained, although the correlation between estrogen and midshaft bone loss was no longer significant. The results for the postmenopausal only group must be viewed cautiously, however, since the estimates of bone loss for those women who went through menopause during the study were much more variable (due to fewer observations for the calculation of slopes of bone mass), as evidenced by standard deviations -70% greater than for the same group using the entire 3-yr worth of measurements.
These data suggest that estrogen replacement therapy might better be given to those with lower endogenous estrogen concentrations. Since endometrial cancer risk may be greater among those with higher estrogen concentrations, treatment of only those with lower estrogen concentrations might provide the greatest benefit (reducing bone loss in those with the most rapid loss) with the least risk (treating only those at the lowest risk of endometrial cancer). Despite considerable controversy, similar arguments could be made with regard to enhancing the possible cardiovascular benefits of estrogen therapy.
Note that we used total estrogen concentrations in our analyses, and these levels would include the free, albuminbound and sex hormone-binding globulin-bound estrogen. Which of these is the biologically active form may vary according to the tissue considered (31). It is possible, at least for E2, that tighter correlations might have been found had we used the free and/or albumin-bound concentrations of estrogens in our analyses. However, the blood PB of the estrogens and androgens that are thought to reflect the biologically active moiety (32) had correlations not dissimilar from the total estrogens. Therefore, it is probable that measurements of the bound and free fractions would not have changed the results measurably.
The value of plasma estrogen concentration as a criterion for the selection of subjects for replacement therapy will depend on the answer to at least two questions. First, how well does a single measurement ofan estrogen reflect the true status of a subject? In this study the median range for El (3-11 measurements per subject) was (17, 19, 20, (33) (34) (35) . Increased bone remodelling has been shown by calcium kinetics studies (17) to accompany estrogen deficiency. BGP has also been shown to be elevated during estrogen deficiency while administration of estrogen returns serum BGP to lower concentrations (19) . In the current study, higher BGP concentrations were associated with more rapid bone loss and with lower estrogen concentrations. In multivariate models that did not include BGP, estrogen was the strongest predictor of rates of change in bone mass. When BGP was added (Tables VII and VIII) , the statistical significance of the effect of estrogen was reduced to marginal or nonsignificance. This suggests that estrogen concentrations are important determinants (risk factors) of the rate of bone remodelling around the time of menopause, and that increased remodelling (BGP as a marker) due to a relative deficiency of estrogen leads to increased bone loss. However, the estrogen effect was not completely removed by the addition of BGP to the multivariable models, and, therefore, other mechanisms for the effect of estrogen may also be important, such as an effect on calcium absorption and vitamin D metabolism (34) or calcitonin secretion (36, 37) . Estrogens have also been postulated to affect plasma phosphate (38) , sensitivity of bone to parathyroid hormone (39) , and other factors. Finally, the intraperson variability in the measurement of BGP would also reduce its ability to eliminate estrogen effects from the general linear models. It is also possible that BGP, as a marker ofbone remodelling, is only coincidentally associated with estrogen action, although this seems unlikely.
T concentrations were in all cases associated with distal rates of change in bone mass. The role of androgens in bone loss will require further study, particularly in other age groups where the effects of estrogens may be reduced.
Potentially important confounding factors influencing bone were also examined. Dietary calcium, was not significantly associated with midshaft loss in both analysis of variance and general linear models. Similarly, although caffeine intake has been reported to have a negative effect on calcium balance (40) , it was not significant in the linear models. Thus, no conclusive evidence was seen to support strong calcium or caffeine effects, although the possibility of such effects cannot be ruled out by this study, since the design lacked adequate statistical power to examine nutritional effects.
Cigarette smoking, other hormones, obesity, and stature also did not achieve statistical significance in this study designed to examine estrogen effects.
Although the dependent variable in this study was bone mass (grams per centimeter), adjustment of these values to bone "density" (grams/centimeter per centimeter) by dividing by bone width did not significantly alter any of these results.
Endogenous estrogen concentrations, perhaps through effects on remodelling, appear to be an important factor in bone loss around the time of menopause. Although mean BGP concentration was a "stronger" predictor of bone loss than estrogen concentrations, the most likely biological mechanism would be that declines in estrogen concentration cause increased bone remodelling, thereby yielding increased serum concentrations of BGP. No data suggested an estrogen (or BGP) threshold effect, nor did bone loss accelerate immediately after cessation of menses. Whereas it remains possible that some event coincident with declines in estrogen production may be responsible for the effects noted, other data supported a primary role for estrogen. For example, even among women with relatively low estrogen concentrations, a relationship between bone loss and estrogen was present. Therapy to prevent osteoporosis has thus far been implemented on uncertain criteria. The results of this study offer some promise in this regard, since those subjects with high BGP and low estrogen concentrations have high rates of bone loss, and might be the best candidates for estrogen replacement therapy.
